• Issue

    American Journal of Hematology: Volume 99, Issue 11

    2057-2252
    November 2024
Previous Issue|Next Issue
Export Citation(s)Download PDF(s)

ISSUE INFORMATION

Free Access

Issue Information

  • Pages: 2057-2059
  • First Published: 10 October 2024

EDITORIAL AND COMMENTARY

The importance of autologous stem cell transplantation in improving outcomes in newly diagnosed patients with multiple myeloma

Morie A. Gertz, 
  • Pages: 2060-2062
  • First Published: 18 September 2024

RESEARCH ARTICLE

Open Access

The seasonal distribution of immune thrombotic thrombocytopenic purpura is influenced by geography: Epidemiologic findings from a multi-center analysis of 719 disease episodes

Jeremy W. Jacobs,  Caroline G. Stanek,  Garrett S. Booth,  Argiris Symeonidis,  Andrew W. Shih,  Elizabeth S. Allen,  Eleni Gavriilaki,  Brenda J. Grossman,  Katerina Pavenski,  Amy Moorehead,  Flora Peyvandi,  Pasquale Agosti,  Ilaria Mancini,  Laura D. Stephens,  Jay S. Raval,  Maria Eva Mingot-Castellano,  Elizabeth P. Crowe,  Laetitia Daou,  Menaka Pai,  Donald M. Arnold,  Marisa B. Marques,  Ryan Henrie,  Tyler W. Smith,  Gayatri Sreenivasan,  Rance C. Siniard,  Lisa R. Wallace,  Chisa Yamada,  Miriam Andrea Duque,  Yanyun Wu,  Thomas J. Harrington,  Diana M. Byrnes,  Aikaterini Bitsani,  Amanda K. Davis,  Danielle H. Robinson,  Quentin Eichbaum,  Cristina A. Figueroa Villalba,  Justin E. Juskewitch,  Georgia Kaiafa,  Eleni Kapsali,  Ellen Klapper,  Ingrid Perez-Alvarez,  Monica S. Klein,  Nikolaos Kotsiou,  Chrysavgi Lalayanni,  Evdokia Mandala,  Fatima Aldarweesh,  Rahaf Alkhateb,  Lisandro Fortuny,  Zois Mellios,  Apostolia Papalexandri,  Meredith G. Parsons,  Annette J. Schlueter,  Christopher A. Tormey,  Cameron Wellard,  Erica M. Wood,  Shiyang Jia,  Allison P. Wheeler,  Amy A. Powers,  Christopher B. Webb,  Sean G. Yates,  Raïda Bouzid,  Paul Coppo,  Evan M. Bloch,  Brian D. Adkins, 
  • Pages: 2063-2074
  • First Published: 13 August 2024
The seasonal distribution of immune thrombotic thrombocytopenic purpura is influenced by geography: Epidemiologic findings from a multi-center analysis of 719 disease episodes

Prior studies have suggested that immune thrombotic thrombocytopenic purpura (iTTP) may display seasonal variation; however, methodologic limitations and sample sizes have diminished the ability to perform a rigorous assessment. This 5-year retrospective study assessed the epidemiology of iTTP and determined whether it displays a seasonal pattern. Patients with both initial and relapsed iTTP (defined as a disintegrin and metalloprotease with thrombospondin type motifs 13 activity <10%) from 24 tertiary centers in Australia, Canada, France, Greece, Italy, Spain, and the US were included. A total of 583 patients experienced 719 iTTP episodes. Significantly more episodes occurred in winter compared to spring and in winter compared to autumn. More cases also occurred in winter compared to summer, but this difference was not statistically significant. Occurrence during winter was most pronounced at sites further from the equator and/or with greater annual temperature variation.

Open Access

Serum iron and transferrin saturation variation are circadian regulated and linked to the harmonic circadian oscillations of erythropoiesis and hepatic Tfrc expression in mice

Cavan Bennett,  Anne Pettikiriarachchi,  Alistair R. D. McLean,  Rebecca Harding,  Marnie E. Blewitt,  Cyril Seillet,  Sant-Rayn Pasricha, 
  • Pages: 2075-2083
  • First Published: 17 August 2024
Open Access

Global characteristics and outcomes of autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma: A study of the worldwide network for blood and marrow transplantation (WBMT)

Laurent Garderet,  Luuk Gras,  Linda Koster,  Laurien Baaij,  Nada Hamad,  Anita Dsouza,  Noel Estrada-Merly,  Parameswaran Hari,  Wael Saber,  Andrew J. Cowan,  Minako Iida,  Shinichiro Okamoto,  Hiroyuki Takamatsu,  Shohei Mizuno,  Koji Kawamura,  Yoshihisa Kodera,  Bor-Sheng Ko,  Christopher Liam,  Kim Wah Ho,  A. Sim Goh,  S. Keat Tan,  Alaa M. Elhaddad,  Ali Bazarbachi,  Qamar un Nisa Chaudhry,  Rozan Alfar,  Mohamed-Amine Bekadja,  Malek Benakli,  Cristobal Augusto Frutos Ortiz,  Eloisa Riva,  Sebastian Galeano,  Francisca Bass,  Hira S. Mian,  Arleigh McCurdy,  Feng Rong Wang,  Ly Meng,  Daniel Neumann,  Mickey Koh,  John A. Snowden,  Stefan Schönland,  Donal P. McLornan,  Patrick John Hayden,  Anna Sureda,  Hildegard T. Greinix,  Mahmoud Aljurf,  Yoshiko Atsuta,  Dietger Niederwieser, 
  • Pages: 2084-2095
  • First Published: 19 August 2024
Open Access

Intra-tumoral and peripheral blood TIGIT and PD-1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma

Jay Gunawardana,  Soi C. Law,  Muhammed B. Sabdia,  Éanna Fennell,  Aoife Hennessy,  Ciara I. Leahy,  Paul G. Murray,  Karolina Bednarska,  Sandra Brosda,  Judith Trotman,  Leanne Berkahn,  Andreea Zaharia,  Simone Birch,  Melinda Burgess,  Dipti Talaulikar,  Justina N. Lee,  Emily Jude,  Eliza A. Hawkes,  Sanjiv Jain,  Karthik Nath,  Cameron Snell,  Fiona Swain,  Joshua W. D. Tobin,  Colm Keane,  Mohamed Shanavas,  Emily Blyth,  Christian Steidl,  Kerry Savage,  Pedro Farinha,  Merrill Boyle,  Barbara Meissner,  Michael R. Green,  Francisco Vega,  Maher K. Gandhi, 
  • Pages: 2096-2107
  • First Published: 17 August 2024
Open Access

Comparative clinical efficacy and safety of biosimilar ABP 959 and eculizumab reference product in patients with paroxysmal nocturnal hemoglobinuria

Austin Kulasekararaj,  Francesco Lanza,  Alexandros Arvanitakis,  Saskia Langemeijer,  Satheesh Chonat,  Anil Tombak,  Vladimir Hanes,  Jia Cao,  Mieke Jill Miller,  Alexander Colbert,  Benjamin Shander,  Daniel T. Mytych,  Vincent Chow,  Haby Henary, 
  • Pages: 2108-2117
  • First Published: 22 August 2024

Long-term outcomes of renal AL amyloidosis patients undergoing autologous stem cell transplantation: Validating the performance of the renal staging system

Eli Muchtar,  Morie A. Gertz,  Raphael Mwangi,  Hamza Hassan,  Angela Dispenzieri,  Nelson Leung,  Francis K Buadi,  David Dingli,  Andrew Staron,  Vaishali Sanchorawala, 
  • Pages: 2118-2126
  • First Published: 29 August 2024
Open Access

Comparison of prognostic scores according to WHO classification in 170 patients with advanced mastocytosis and C-finding treated with midostaurin

Maël Heiblig,  Clément Gourguechon,  Philippe Guilpain,  Cristina Bulai-Livideanu,  Stéphane Barete,  Yannick Chantran,  Julie Agopian,  Fabienne Brenet,  Patrice Dubreuil,  Jérémie Lespinasse,  Richard Lemal,  Olivier Tournilhac,  Louis Terriou,  David Launay,  Laurence Bouillet,  Catharina Chatain,  Ghandi Damaj,  Thomas Ballul,  Celine Greco,  Laura Polivka,  Laurent Frenzel,  Cécile Meni,  Hassiba Bouktit,  Dina Benabou,  Caroline Gaudy-Marqueste,  Marie Gousseff,  Edwige Le Mouel,  Antoine Neel,  Dana Ranta,  Roland Jaussaud,  Thierry Jo Molina,  Julie Bruneau,  Patrick Villarese,  Ludovic Lhermitte,  Leila Maouche-Chrétien,  Marie Temple,  Olivier Kosmider,  Rose-Marie Javier,  Fabien Pelletier,  Florence Castelain,  Frederique Retornaz,  Quentin Cabrera,  Patricia Zunic,  Marie Pierre Gourin,  Ewa Wierzbicka–Hainaut,  Jean François Viallard,  Christian Lavigne,  Cyrille Hoarau,  Isabelle Durieu,  Sophie Dimicoli-Salazar,  Jose Miguel Torregrosa-Diaz,  Mathieu Wemeau,  Angèle Soria,  Michel Arock,  Christine Bodemer,  Olivier Lortholary,  Olivier Hermine,  Julien Rossignol, 
  • Pages: 2127-2139
  • First Published: 17 September 2024
Comparison of prognostic scores according to WHO classification in 170 patients with advanced mastocytosis and C-finding treated with midostaurin

The AdvSM subtypecombined with the MARS score has the best prognostic value for overall survivalin patients with AdvSM and at least one C-finding treated with midostaurin. Thus,five subgroups of AdvSM patients with different outcomes are identified. Thepresence of an abnormal karyotype or portal hypertension is associated with therisk of AML transformation in patients with SM-AHN.

Machine-learning based subgroups of AL amyloidosis and cumulative incidence of mortality and end stage kidney disease

Shankara K. Anand,  Andrew Staron,  Lisa M. Mendelson,  Tracy Joshi,  Natasha Burke,  Vaishali Sanchorawala,  Ashish Verma, 
  • Pages: 2140-2151
  • First Published: 11 September 2024

CRITICAL REVIEW

Advances in sickle cell retinopathy screening techniques, tests, and practices: A systematic review

Olivia W. Cummings,  Sara Rahman,  Lauren Fletcher,  Adrienne W. Scott, 
  • Pages: 2152-2163
  • First Published: 23 July 2024
Open Access

Disease burden, management strategies, and unmet needs in α-thalassemia due to hemoglobin H disease

Ashutosh Lal,  Vip Viprakasit,  Elliott Vichinsky,  Yongrong Lai,  Meng-Yao Lu,  Antonis Kattamis, 
  • Pages: 2164-2177
  • First Published: 22 July 2024

UPDATES IN CLINICAL TRIALS FOR HEMATOLOGICAL DISEASES

Free Access

2025 update on clinical trials in immune thrombocytopenia

Hanny Al-Samkari, 
  • Pages: 2178-2190
  • First Published: 06 August 2024
2025 update on clinical trials in immune thrombocytopenia

Summary of major novel and repurposed agents currently in clinical development for immune thrombocytopenia.

ANNUAL CLINICAL UPDATES IN HEMATOLOGICAL MALIGNANCIES

Free Access

Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring

Elias Jabbour,  Hagop Kantarjian, 
  • Pages: 2191-2212
  • First Published: 02 August 2024

CLINICAL PEARLS IN BLOOD DISEASES

MORPHOLOGY UPDATE

Open Access

Where hematology meets rheumatology—VEXAS syndrome

Hajer Oun,  William Gordon,  Mike Leach,  Barbara J. Bain, 
  • Pages: 2213-2214
  • First Published: 30 July 2024

IMAGES IN HEMATOLOGY

Open Access

Purplish granules as a cytological signature of cortical developmental disorders caused by pathogenic variants in WDR81

Baptiste Le Calvez,  Thomas Besnard,  Benjamin Cogne,  Stéphane Bézieau,  Marie C. Béné,  Claire Beneteau,  Marion Eveillard, 
  • Pages: 2215-2218
  • First Published: 17 April 2024

CORRESPONDENCE

Free Access

Imatinib versus newer generation TKIs for upfront therapy in chronic phase chronic myeloid leukemia: What is the rationale for paying more to get the same survival benefit?

Jeffrey H. Lipton, 
  • Pages: 2219-2221
  • First Published: 14 August 2024
Free Access

Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma

Samer Al Hadidi,  Obada Ababneh,  Carolina Schinke,  Sharmilan Thanendrarajan,  Clyde Bailey,  Guido Tricot,  John Shaughnessy Jr,  Fenghuang Zhan,  Jeffrey Sawyer,  Eric R. Siegel,  Maurizio Zangari,  Bart Barlogie,  Frits van Rhee, 
  • Pages: 2222-2224
  • First Published: 07 August 2024
Free Access

Timing and outcomes of second-line therapy in the era of daratumumab-based frontline therapy in AL amyloidosis

Abdul-Hamid Bazarbachi,  Divaya Bhutani,  Jai Radhakrishnan,  Markus Mapara,  Mathew S. Maurer,  Suzanne Lentzsch,  Rajshekhar Chakraborty, 
  • Pages: 2225-2228
  • First Published: 03 August 2024
Free Access

A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia

Wei-Ying Jen,  Elias Jabbour,  Nicholas J. Short,  Ghayas C. Issa,  Fadi G. Haddad,  Nitin Jain,  Naveen Pemmaraju,  Naval G. Daver,  Lucia Masarova,  Gautam Borthakur,  Kelly Chien,  Rebecca Garris,  Hagop M. Kantarjian, 
  • Pages: 2229-2232
  • First Published: 28 August 2024
A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia

Twenty adults with newly diagnosed (ND) or relapsed/refractory (RR) Ph-positive acute lymphoblastic leukemia (ALL), or chronic myeloid leukemia in lymphoid blast phase (CML-LBP), were treated with mini-hyperCVD, ponatinib, and blinatumomab. Complete molecular response was achieved in 78% of ND patients, while CR/CRi was achieved in 100% of RR and CML-LBP. The 3-year overall survival rate was 76% (95% CI, 47%–90%).

Free Access

Self-pay laboratory charges for iron deficiency diagnosis in the Boston and New Haven metropolitan areas

Layla Van Doren,  Carlo Brugnara, 
  • Pages: 2233-2235
  • First Published: 09 August 2024
Free Access

White blood cell count levels are associated with inflammatory response and constitute independent outcome predictors in adult patients with acute myeloid leukemia aged <60 years

Michael Ozga,  Deedra Nicolet,  Krzysztof Mrózek,  Christopher J. Walker,  James S. Blachly,  Jessica Kohlschmidt,  Shelley Orwick,  Andrew J. Carroll,  Richard A. Larson,  Jonathan E. Kolitz,  Bayard L. Powell,  Richard M. Stone,  John C. Byrd,  Ann-Kathrin Eisfeld,  Alice S. Mims, 
  • Pages: 2236-2240
  • First Published: 16 September 2024
Free Access

Successful 13-year ongoing remission with C5 inhibitor therapy following renal transplant in atypical hemolytic uremic syndrome

Mariam A. Mostafa,  Martin Zand,  Jeremy Taylor,  Peter Kouides, 
  • Pages: 2241-2243
  • First Published: 23 August 2024
Free Access

Secondary acquisition of the Philadelphia chromosome in acute lymphoblastic leukemia

Qiudan Shen,  Elias J. Jabbour,  Guilin Tang,  Hong Fang,  Wei Wang,  Nicholas J. Short,  M. James You,  L. Jeffrey Medeiros,  Shimin Hu, 
  • Pages: 2244-2248
  • First Published: 17 August 2024
Free Access

Quadruplets in newly diagnosed transplant-ineligible multiple myeloma

Rajshekhar Chakraborty,  Hira Mian, 
  • Pages: 2249-2252
  • First Published: 10 September 2024